Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Cash from Operations (2016 - 2025)

Sunshine Biopharma (SBFM) has disclosed Cash from Operations for 14 consecutive years, with 727800.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Operations rose 46.35% year-over-year to 727800.0, compared with a TTM value of 7126728.0 through Sep 2025, up 39.65%, and an annual FY2024 reading of 12531180.0, down 42.8% over the prior year.
  • Cash from Operations was 727800.0 for Q3 2025 at Sunshine Biopharma, up from 1273432.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 297355.0 in Q1 2021 and bottomed at 4577784.0 in Q2 2024.
  • Average Cash from Operations over 5 years is 1689412.84, with a median of 1304208.0 recorded in 2022.
  • The sharpest move saw Cash from Operations crashed 858.16% in 2021, then surged 72.18% in 2025.
  • Year by year, Cash from Operations stood at 312113.0 in 2021, then tumbled by 619.81% to 2246612.0 in 2022, then decreased by 19.72% to 2689676.0 in 2023, then decreased by 26.84% to 3411661.0 in 2024, then surged by 78.67% to 727800.0 in 2025.
  • Business Quant data shows Cash from Operations for SBFM at 727800.0 in Q3 2025, 1273432.0 in Q2 2025, and 1713835.0 in Q1 2025.